Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

GlobalData, September 2011, Pages: 80

Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Amyotrophic Lateral Sclerosis Therapeutics market. The report identifies the key trends shaping and driving the global Amyotrophic Lateral Sclerosis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Amyotrophic Lateral Sclerosis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Amyotrophic Lateral Sclerosis Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Amyotrophic Lateral Sclerosis Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Amyotrophic Lateral Sclerosis Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Amyotrophic Lateral Sclerosis Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Amyotrophic Lateral Sclerosis Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Amyotrophic Lateral Sclerosis Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Amyotrophic Lateral Sclerosis Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Amyotrophic Lateral Sclerosis Therapeutics market landscape? – Identify, understand and capitalize.

1
1

1.1 List of Tables
1.2 List of Figures
2 Amyotrophic Lateral Sclerosis Therapeutics: Introduction
2.1 Overview
2.2 Epidemiology
2.3 Etiology and Pathophysiology
2.4 Symptoms
2.5 Diagnosis
2.6 Treatment and Management Pattern
2.7 Referral Pathway
2.8 Pipeline Report Guidance
3 Amyotrophic Lateral Sclerosis Therapeutics: Market Characterization
3.1 Amyotrophic Lateral Sclerosis Therapeutics Market Size (2005 - 2010) - Global
3.2 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018) - Global
3.3 Amyotrophic Lateral Sclerosis Therapeutics Market Size (2005 - 2010): The US
3.4 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010-2018): The US
3.5 Amyotrophic Lateral Sclerosis Therapeutics Market (2005 - 2010): France
3.6 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018): France
3.7 Amyotrophic Lateral Sclerosis Therapeutics Market (2005 - 2010): Germany
3.8 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018): Germany
3.9 Amyotrophic Lateral Sclerosis Therapeutics Market (2005 - 2010): Italy
3.10 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018): Italy
3.11 Amyotrophic Lateral Sclerosis Therapeutics Market (2005 - 2010): Spain
3.12 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018): Spain
3.13 Amyotrophic Lateral Sclerosis Therapeutics Market (2005 - 2010): The UK
3.14 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018): The UK
3.15 Amyotrophic Lateral Sclerosis Therapeutics Market (2005 - 2010): Japan
3.16 Amyotrophic Lateral Sclerosis Therapeutics Market Forecast (2010 - 2018): Japan
3.17 Drivers and Barriers for the Amyotrophic Lateral Sclerosis Therapeutics Market
3.17.1 Drivers for the Amyotrophic Lateral Sclerosis Therapeutics Market
3.17.2 Barriers for the Amyotrophic Lateral Sclerosis Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 Amyotrophic Lateral Sclerosis Therapeutics: Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the Amyotrophic Lateral Sclerosis Therapeutics Market
4.3.1 Rilutek (riluzole)
5 Amyotrophic Lateral Sclerosis Therapeutics: Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Amyotrophic Lateral Sclerosis Therapeutics Pipeline – Pipeline by Phases of Development
5.3.1 Amyotrophic Lateral Sclerosis Therapeutics – Phase III Pipeline
5.3.2 Amyotrophic Lateral Sclerosis Therapeutics – Phase II Pipeline
5.3.3 Amyotrophic Lateral Sclerosis Therapeutics – Phase I Pipeline
5.3.4 Amyotrophic Lateral Sclerosis Therapeutics – Preclinical Pipeline
5.3.5 Amyotrophic Lateral Sclerosis Therapeutics – Discovery Pipeline
5.3.6 Amyotrophic Lateral Sclerosis Therapeutics – Phase Unknown
5.4 Amyotrophic Lateral Sclerosis Therapeutics Market – Pipeline by Mechanism of Action
5.5 Technology Trends Analytical Framework
5.6 ALS Therapeutics – Most Promising Drugs Under Development
5.7 Molecule Profile for Promising Drugs under Development
5.7.1 Dexpramipexole (KNS-760704)
5.7.2 Olesoxime (TRO 19622)
5.7.3 Radicut
5.7.4 ALS-02
5.8 Profile for Other Drugs under Clinical Development
5.8.1 E0302 (mecobalamin)
6 Amyotrophic Lateral Sclerosis Therapeutics: Clinical Trials Mapping
6.1 Clinical Trials by Country (US, EU5 & Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Key Companies Participating in Therapeutics Clinical Trials
7 Amyotrophic Lateral Sclerosis Therapeutics: Stategic Assessment
7.1 Key Events Impacting on the Future Market
7.2 Amyotrophic Lateral Sclerosis Therapeutics: Implications for Future Market Competition
8 Amyotrophic Lateral Sclerosis Therapeutics: Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 The Avicena Group Inc.
8.2.2 Biogen Idec/Knopp Bioscience Inc.
8.2.3 Actelion Pharmaceuticals Ltd.
8.2.4 Mitsubishi Tanabe Pharma Corporation
8.2.5 Eisai Co. Ltd
8.2.6 Other Companies in the Amyotrophic Lateral Sclerosis Therapeutics Market
9 Amyotrophic Lateral Sclerosis Therapeutics: Licensing and Partnership Deals
10 Amyotrophic Lateral Sclerosis Therapeutics: Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Incidence of ALS in Top Seven Countries and the World
Table 2: EI Escorial Criteria for Diagnosing ALS
Table 3: Drugs for the Symptomatic Treatment of ALS
Table 4: Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Revenue($m), 2005-2010
Table 5: Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Forecast($m), 2010-2018
Table 6: Amyotrophic Lateral Sclerosis Therapeutics Market, The US, Revenue($m), 2005-2010
Table 7: Amyotrophic Lateral Sclerosis Therapeutics Market, The US, Forecast($m), 2010-2018
Table 8: Amyotrophic Lateral Sclerosis Therapeutics Market, France, Revenue($m), 2005-2010
Table 9: Amyotrophic Lateral Sclerosis Therapeutics Market, France, Forecast($m), 2010-2018
Table 10: Amyotrophic Lateral Sclerosis Therapeutics Market, Germany, Revenue($m), 2005-2010
Table 11: Amyotrophic Lateral Sclerosis Therapeutics Market, Germany, Forecast ($m), 2010-2018
Table 12: Amyotrophic Lateral Sclerosis Therapeutics Market, Italy, Revenue ($m), 2005-2010
Table 13: Amyotrophic Lateral Sclerosis Therapeutics Market, Italy, Forecast ($m), 2010-2018
Table 14: Amyotrophic Lateral Sclerosis Therapeutics Market, Spain, Revenue ($m), 2005-2010
Table 15: Amyotrophic Lateral Sclerosis Therapeutics Market, Spain, Forecast ($m), 2010-2018
Table 16: Amyotrophic Lateral Sclerosis Therapeutics Market, UK, Revenue ($m), 2005-2010
Table 17: Amyotrophic Lateral Sclerosis Therapeutics Market, UK, Forecast ($m), 2010-2018
Table 18: Amyotrophic Lateral Sclerosis Therapeutics Market, Japan, Revenue ($m), 2005-2010
Table 19: Amyotrophic Lateral Sclerosis Therapeutics Market, Japan, Forecast ($m), 2010-2018
Table 20: Amyotrophic Lateral Sclerosis Therapeutics – Phase III Clinical Pipeline, 2011
Table 21: Amyotrophic Lateral Sclerosis Therapeutics – Phase II Clinical Pipeline, 2011
Table 22: Amyotrophic Lateral Sclerosis Therapeutics – Phase l Pipeline, 2011
Table 23: Amyotrophic Lateral Sclerosis Therapeutics – Preclinical Pipeline, 2011
Table 24: Amyotrophic Lateral Sclerosis Therapeutics – Discovery Pipeline, 2011
Table 25: Amyotrophic Lateral Sclerosis Therapeutics – Phase Unknown, 2011
Table 26:Amyotrophic Lateral Sclerosis Therapeutics – Most Promising Drugs Under Development, 2011
Table 27: A Brief History of dexpramipexole
Table 28: A Brief History of olesoxime
Table 29: Amyotrophic Lateral Sclerosis Therapeutics, Clinical Trials by Country,2011
Table 30: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Phase of Development, 2011
Table 31: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2011
Table 32: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Overall Sponsors, 2011
Table 33: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011
Table 34: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Top Companies, 2011
Table 35: The Avicena Group Inc. - CNS Pipeline Portfolio, 2011
Table 36: Biogen Idec. – CNS Pipeline Portfolio, 2011
Table 37: Knopp Bioscience Inc. – CNS Pipeline Portfolio, 2011
Table 38: Actelion Pharmaceuticals Ltd - CNS Pipeline Portfolio, 2011
Table 39: Mitsubishi Tanabe Pharma Corporation – CNS Pipeline Portfolio, 2011
Table 40: Eisai Co. Ltd. – CNS Pipeline Portfolio, 2011
Table 41: Other Companies in the Pipeline, 2011
Table 42: Licensing and Partnership Deals, 2010-2011

1.2 List of Figures
Figure 1: Normal and ALS-Affected Nerve Cells
Figure 2: Normal and ALS affected Motor Neurons/Muscles
Figure 3: Management Algorithm for Sialorrhea in Patients with ALS
Figure 4: Management Algorithm for Nutrition Deficiency in Patients with ALS
Figure 5: Management Algorithm for Respiratory Problems in Patients with ALS
Figure 6: Amyotrophic Lateral Sclerosis Therapeutics, Referral Pathway
Figure 7: Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Revenue($m), 2005-2010
Figure 8: Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Forecast ($m), 2010-2018
Figure 9: Amyotrophic Lateral Sclerosis Therapeutics Market, The US, Revenue($m), 2005-2010
Figure 10: Amyotrophic Lateral Sclerosis Therapeutics Market, The US, Forecast($m), 2010-2018
Figure 11: Amyotrophic Lateral Sclerosis Therapeutics Market, France, Revenue($m), 2005-2010
Figure 12: Amyotrophic Lateral Sclerosis Therapeutics Market, France, Forecast($m), 2010-2018
Figure 13: Amyotrophic Lateral Sclerosis Therapeutics Market, Germany, Revenue($m), 2005-2010
Figure 14: Amyotrophic Lateral Sclerosis Therapeutics Market, Germany, Forecast ($m), 2010-2018
Figure 15: Amyotrophic Lateral Sclerosis Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 16: Amyotrophic Lateral Sclerosis Therapeutics Market, Italy, Forecast ($m), 2010-2018
Figure 17: Amyotrophic Lateral Sclerosis Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 18: Amyotrophic Lateral Sclerosis Therapeutics Market, Spain, Forecast ($m), 2010-2018
Figure 19: Amyotrophic Lateral Sclerosis Therapeutics Market, UK, Revenue ($m), 2005-2010
Figure 20: Amyotrophic Lateral Sclerosis Therapeutics Market, UK, Forecast ($m), 2010-2018
Figure 21: Amyotrophic Lateral Sclerosis Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 22: Amyotrophic Lateral Sclerosis Therapeutics Market, Japan, Forecast ($m), 2010-2018
Figure 23: Opportunity and Unmet Need in the Amyotrophic Lateral Sclerosis Therapeutics Market, 2010
Figure 24: Strategic Competitor Assessment of the Major Marketed Products for Amyotrophic Lateral Sclerosis, 2011
Figure 25: Amyotrophic Lateral Sclerosis Therapeutics, Molecular Structure of Rilutek
Figure 26: Amyotrophic Lateral Sclerosis Therapeutics, Pipeline by Phase of Development, 2011
Figure 27: Amyotrophic Lateral Sclerosis Therapeutics Market – Pipeline by Mechanism of Action, 2011
Figure 28: Technology Trends Analytic Framework of the Amyotrophic Lateral Sclerosis Therapeutics Pipeline, 2011
Figure 29: Technology Trends Analytic Framework of the Amyotrophic Lateral Sclerosis Therapeutics Pipeline - Description, 2011
Figure 30: Amyotrophic Lateral Sclerosis Therapeutics, Molecular Structure of dexpramipexole
Figure 31: Amyotrophic Lateral Sclerosis Therapeutics, Molecular Structure of olesoxime
Figure 32: Amyotrophic Lateral Sclerosis Therapeutics - Clinical Trials by Country, 2011
Figure 33: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Phase of Development, 2011
Figure 34: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Trial Status, 2011
Figure 35: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Overall Sponsors, 2011
Figure 36: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Prominent Sponsors, 2011
Figure 37: Amyotrophic Lateral Sclerosis Therapeutics, Global, Clinical Trials by Top Companies, 2011
Figure 38: Amyotrophic Lateral Sclerosis Therapeutics Market, Drivers and Barriers, 2011
Figure 39: Implications for Future Market Competition in the Amyotrophic Lateral Sclerosis Therapeutics Market, 2011
Figure 40: Amyotrophic Lateral Sclerosis Therapeutics – Clinical Pipeline by Company, 2011

GlobalData, the industry analysis specialist, has released its new report, “Amyotrophic Lateral Sclerosis (ALS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Amyotrophic Lateral Sclerosis(ALS) therapeutics market. The report identifies the key trends shaping and driving the market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global ALS therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The Amyotrophic Lateral Sclerosis (ALS) Therapeutics Market is Forecast to Show Slow Growth Up to 2018

The global market for amyotrophic lateral sclerosis (ALS) therapeutics was valued at approximately $168m in 2010. Rilutek (riluzole) is the only approved drug prescribed for the treatment of ALS.It is a disease modifying drug which helps to increase the patient survival rate by a few months. Nevertheless,its low efficacy and moderate safety as well as its high annual cost of therapy limits the use of Rilutek among the medical practitioners.However, its high cost of therapy also serves to give Rilutek a significant share of the market in terms of value. During the forecast period 2010-2018, the ALS therapeutics market is expected to witness the patent expiry of Rilutek and the approval of dexpramipexole, olesoxime and Radicut (edaravone). The launch of these new products will serve to negate the impact of the patent expiry of Rilutek and drive the growth of the market to reach approximately $234.8m by 2018 at a Compound Annual Growth Rate (CAGR) of 4.3%. The promising pipeline candidate, dexpramipexole received fast track approval from the US Food and Drug Administration (FDA) and orphan drug status by both the US FDA and the European Medicines Agency (EMEA) in 2009,Olesoxime was granted orphan drug status by the US FDA and Orphan Medicinal Product designation by the European Commission in the EU in 2005.Radicut was assigned orphan drug status in Japan in 2005.Therefore these three new drugs which are expected to enter the market by 2014 will help to drive the market growth. The challenging clinical development environment, due to a lack of understanding of the pathophysiology of ALS, poses a significant barrier for the approval of new drugs in the ALS therapeutics market. This is borne out by the fact that there have been no major drug approvals for the treatment of ALS in the last decade following the approval of Rilutek in Japan in 2001. Moreover, in 2002, the development of Xaliproden by erstwhile Sanofi-Synthelabo Inc. (currently Sanofi), had been terminated in its Phase III development stage, due to fewer survival benefits observed in the trial when compared with the expected outcome.

Amyotrophic Lateral Sclerosis Therapeutics Market, Global, Revenues ($m), 2005-2018

Source: GlobalData; Amyotrophic Lateral Sclerosis Association, the US; NINDS, the US; American Academy of Neurology, the US; National Health Services, the UK; Prevalence of rare diseases: Bibliographic data, Orphanet Report Series, May 2011; International Alliance of ALS/MND

The Avicena Group Inc.
Biogen Idec/Knopp Bioscience Inc.
Actelion Pharmaceuticals Ltd.
Mitsubishi Tanabe Pharma Corporation
Eisai Co. Ltd

Customers who bought this item also bought

• Amyotrophic Lateral Sclerosis – Analysis and Market Forecasts to 2019
• Stem Cell Approaches in Neurology and Psychiatry: 25 Trend Setters for 2013 - 3rd Biennial Report
• Endpoints-Clinical Trials in Orphan Diseases - Highest Number of Terminated Trials Focused on Mulitiple Myeloma
• Lou Gehrigs Disease - Global Strategic Business Report
• The Stem Cell Market Outlook
• Multiple Sclerosis Therapeutics - Global Strategic Business Report
• Global Multiple Sclerosis Drug Pipeline Capsule - 2012
• The Neurotechnology Industry 2012 Report
• TreatmentTrends®: US Multiple Sclerosis 2011 (Wave 4)
• Medical Nutrition - A Global Market Overview